PBT swung to $3.6m profit but a $12.1m tax charge widened NPAT loss to $8.5m

What changed

Revenue lifted 15.4% to NZD 168.7m from NZD 146.3m. Profit before tax swung to a NZD 3.6m profit from a NZD 3.0m loss in FY23, a 220.6% improvement, and management's Underlying EBITDA rose 47% to NZD 20.9m. Despite that, NPAT deteriorated from a NZD 2.1m loss to a NZD 8.5m loss — a NZD 6.4m widening — because a NZD 12.1m income tax expense was booked against only NZD 3.6m of pre-tax profit, implying an effective tax rate of roughly –335.8%. Operating cash flow was NZD 14.1m and capex NZD 4.1m, producing around NZD 10.0m of pre-lease free cash flow. Net debt fell 26.5% to NZD 73.5m with no short-term debt remaining, and a 0.7 cps final dividend was declared, resuming distributions after none in FY23.

What matters

• PBT is the cleaner read this year. The PBT-to-NPAT growth gap is 523.6pp. Management presents this as a "record" result on EBITDA and PBT, but the statutory loss worsened on an oversized tax charge that is not reconciled in the extracted material. Until that tax line is explained, reported NPAT understates, rather than reflects, the underlying operating shift.
• Deleveraging is genuine. Net debt of NZD 73.5m against Underlying EBITDA of NZD 20.9m implies leverage of about 3.5x, down from roughly 7.0x a year earlier on management's disclosed net-debt reduction. Pre-lease FCF of NZD 10.0m comfortably covers the small declared dividend (payout of about 20% of pre-lease FCF), so capital-return resumption looks affordable on cash, even though it is not covered by statutory NPAT.
• EBITDAR per occupied bed up 24% to NZD 24.7k, pointing to operating leverage from the July 2023 funding step-up flagged at the half, rather than pure volume growth.

Expectations

No FY25 guidance, forward-work balance, or quantified target was disclosed in the extracted release. Against HY24 shape, the second half was marginally stronger on revenue (50.6% of FY) and flat on EBITDA (49.8%), but NPAT deteriorated sharply in H2: HY24 NPAT was a NZD 1.4m profit, implying H2 NPAT of approximately –NZD 9.9m. That H2 swing is consistent with the tax charge landing in the second half rather than with an operating breakdown, but the release excerpts do not confirm the timing. The result supports the claim of improving underlying profitability and cash generation; it does not support any read on FY25 margin trajectory or funding outlook.

Quality of result

Revenue and Underlying EBITDA growth appear durable, driven by tariff/funding changes effective 1 July 2023 and premium-room accommodation supplement uplift already flagged at the half. Cash conversion is reasonable: OCF-to-EBITDA of 67.5% is modest but not alarming for an aged-care operator carrying lease obligations, and pre-lease FCF of NZD 10.0m is real cash. Working-capital metrics (receivables ~25.6 days, inventory ~1.2 days) look unremarkable, though prior-year comparatives are not provided. The main quality caveat is the non-GAAP framing: "Underlying" EBITDA is not reconciled to statutory earnings in the extracted material, and the NZD 12.1m tax expense on NZD 3.6m of PBT is not explained. Post-lease FCF cannot be derived from the disclosures provided.

Unresolved

• What drives the NZD 12.1m income tax expense against NZD 3.6m of PBT — deferred tax movement, non-deductible items, prior-year true-up, or a change in recognised tax assets?
• What is the full-period dividend (the 0.7 cps appears to be the sole FY24 declaration) and what is the stated payout policy going forward?
• What sits between statutory earnings and the Underlying EBITDA measure; without a reconciliation, the 47% uplift cannot be independently validated.
• Prior-year comparatives for operating cash flow, capex, trade debtors and gross borrowings are not in the extracted data, limiting trend verification on cash conversion and working capital.
• No segment, concentration, occupancy, or forward-work disclosure is available in the extracted excerpts.

This briefing cannot assess FY25 operating trajectory, tax-line sustainability, or valuation, because none of guidance, a tax reconciliation, or share-price/NTA data is present in the supplied material.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.